XENON PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
XENON PHARMACEUTICALS INC. (XENE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $25.39 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-02-26
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2020 was 7.43 CAD/shares, a 10.37% decline from fiscal 2019.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2019 was 8.29 CAD/shares, a 23.73% increase from fiscal 2018.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2018 was 6.70 CAD/shares, a 10.19% decline from fiscal 2017.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2017 was 7.46 CAD/shares, a 27.22% decline from fiscal 2016.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2020-12-31 | 7.43 CAD/shares 10-K · filed 2021-03-01 |
| 2019-12-31 | 8.29 CAD/shares 10-K · filed 2020-03-09 |
| 2018-12-31 | 6.70 CAD/shares 10-K · filed 2019-03-06 |
| 2017-12-31 | 7.46 CAD/shares 10-K · filed 2018-03-07 |
| 2016-12-31 | 10.25 CAD/shares 10-K · filed 2017-03-08 |
| 2015-12-31 | 7.90 CAD/shares 10-K · filed 2016-03-08 |
| 2014-12-31 | 3.88 CAD/shares 10-K · filed 2015-03-12 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $25.39 10-K · filed 2026-02-26 |
| 2024-12-31 | $22.04 10-K · filed 2025-02-27 |
| 2023-12-31 | $18.62 10-K · filed 2024-02-29 |
| 2022-12-31 | $14.43 10-K · filed 2023-03-01 |
| 2021-12-31 | $8.36 10-K · filed 2022-03-01 |
| 2020-12-31 | $5.83 10-K · filed 2021-03-01 |
| 2019-12-31 | $6.37 10-K · filed 2020-03-09 |
| 2018-12-31 | $5.17 10-K · filed 2019-03-06 |
| 2017-12-31 | $5.74 10-K · filed 2018-03-07 |
| 2016-12-31 | $7.73 10-K · filed 2017-03-08 |
| 2015-12-31 | $6.19 10-K · filed 2016-03-08 |
| 2014-12-31 | $3.35 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |